AZN - AstraZeneca PLC
36.80 -0.05 (-0.15%)
After hours: 4:11PM EDT
| Previous Close | 37.05 |
| Open | 36.83 |
| Bid | 0.00 x 2900 |
| Ask | 38.00 x 1100 |
| Day's Range | 36.68 - 36.91 |
| 52 Week Range | 28.43 - 37.30 |
| Volume | 4,918,286 |
| Avg. Volume | 4,034,030 |
| Market Cap | 91.736B |
| Beta | 0.57 |
| PE Ratio (TTM) | 31.09 |
| EPS (TTM) | 1.18 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.97%) |
| Ex-Dividend Date | 2018-02-15 |
| 1y Target Est | 38.89 |
- American City Business Journals•5 hours ago
Why Big Pharma is finally discovering the Bay Area
AstraZeneca formally opened its 163,000-square-foot lab and office complex Tuesday in HCP Inc.'s Britannia Cove in South San Francisco. It joins Merck and Bristol-Myers Squibb as traditional drug maker to expand operations in the Bay Area.
Market Realist•yesterdayWhy Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?
Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of AZN.L earnings conference call or presentation 18-May-18 11:00am GMT
Q1 2018 AstraZeneca PLC Earnings Call
- Investor's Business Daily•2 days ago
Stocks Move On Trade Talks As Dow Finds An Unlikely Top Performer In GE
Stocks recovered part of their late-morning slide as the market showed it's paying keen attention to trade talks with China.
- Investopedia•2 days ago
AstraZeneca Gets FDA Nod for Hyperkalaemia Drug
Hyperkalemia a serious condition of having elevated potassium levels in the blood that is linked with cardiovascular, renal and metabolic diseases. The problems of hyperkalemia gets severe for patients who are suffering from heart failure (HF) or chronic kidney disease (CKD), as a few medications used for treating these diseases increase the levels of potassium in the body.
- MarketWatch•2 days ago
U.K. stocks log record close as U.S.-China ease trade-war tensions
U.K. stocks rose sharply on Monday, scoring a record close, as traders welcomed news over the weekend that China and the U.S. reached an agreement that eases trade tensions between the world’s two largest economies. The FTSE 100 index (^FTSE) rose 1% to end at 7,859.17, taking out its previous closing high of 7,787.97, hit last Thursday. A weaker pound tends to boost the FTSE 100, as the index’s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.
- Zacks•2 days ago
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Reuters•3 days agoAstraZeneca potassium drug finally approved, threatening Vifor
The decision by U.S. regulators to finally approve AstraZeneca's (AZN.L) much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion (2 billion pounds) in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's (VIFN.S) rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.
- Reuters•3 days ago
AstraZeneca potassium drug finally approved, threatening Vifor
The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.
- Business Wire•5 days ago
LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia
AstraZeneca today announced that the US Food and Drug Administration has approved LOKELMATM , formerly ZS-9, for the treatment of
- Investor's Business Daily•5 days ago
AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.
Yahoo Finance•5 days agoTrump talks to Postmaster General about Amazon, plus a retail wrap-up and royal wedding preview
If you’re looking for a winner this week, the energy sector is the top performer, up 2.7%. Let’s take a look at some of today’s winners and losers. Stocks in the red include Campbell Soup, as the stock plummets with news that the CEO is retiring.
- Zacks•5 days ago
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Motley Fool•5 days agoAstrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
AZN earnings call for the period ending March 31, 2018.
Reuters•5 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
Reuters•5 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
- MarketWatch•5 days ago
U.K. stocks fall from record as AstraZeneca, mining stocks decline
FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.
- InvestorPlace•5 days ago
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales
AstraZeneca plc’s earnings report for the first quarter of the year includes earnings per share of 27 cents. This is down from its earnings per share of 48 cents reported in the same period of the year prior. During the first quarter of 2018, AstraZeneca plc reported profit of $316 million.
- Zacks•6 days ago
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
- Market Realist•6 days ago
European Markets Are Mixed Early on May 18
The United Kingdom’s FTSE 100 Index started this week on a mixed note but regained strength as the week progressed. On Thursday, the FTSE 100 Index surged and closed higher at a fresh record high price levels. On May 18, the FTSE 100 Index opened slightly lower and consolidated near all-time high price levels in the morning session.
- Benzinga•6 days ago
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...
- MarketWatch•6 days ago
Italian stocks lead Europe lower as politics spook traders
The Stoxx Europe 600 index (^STOXX) tipped about 0.1% lower to 395.44, on track to break a three-day winning run. Italy’s FTSE MIB Index (MTAA:FTSEMIB.MI) slumped 1% to 23,564.03, as political developments in the country flustered markets. In the U.K., the FTSE 100 index (^FTSE) slipped 0.2% to 7,774.39, but was still on track for a 0.6% weekly advance.
Reuters•6 days agoAstraZeneca insists future is bright after big Crestor sales hit
AstraZeneca's (AZN.L) first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million (663 million pounds), well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.
- Reuters•6 days ago
AstraZeneca insists future is bright after big Crestor sales hit
AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.
- Associated Press•6 days ago
Astrazeneca: 1Q Earnings Snapshot
On a per-share basis, the Cambridge, Britain-based company said it had net income of 27 cents. Earnings, adjusted for non-recurring costs, came to 48 cents per share. The results topped Wall Street expectations. ...
